NZ504025A - Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease - Google Patents

Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease

Info

Publication number
NZ504025A
NZ504025A NZ504025A NZ50402598A NZ504025A NZ 504025 A NZ504025 A NZ 504025A NZ 504025 A NZ504025 A NZ 504025A NZ 50402598 A NZ50402598 A NZ 50402598A NZ 504025 A NZ504025 A NZ 504025A
Authority
NZ
New Zealand
Prior art keywords
vdrr
polypeptides
vitamin
receptor related
inflammatory disease
Prior art date
Application number
NZ504025A
Inventor
Anders Berkenstam
Mats Dahlberg
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9703745A external-priority patent/SE9703745D0/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NZ504025A publication Critical patent/NZ504025A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. Furthermore, the novel VDRR polypeptide can be the polypeptide designated VDRRg, which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.
NZ504025A 1997-10-14 1998-08-31 Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease NZ504025A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9703745A SE9703745D0 (en) 1997-10-14 1997-10-14 New receptors
SE9801148A SE9801148D0 (en) 1997-10-14 1998-03-31 New receptors
PCT/SE1998/001548 WO1999019354A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof

Publications (1)

Publication Number Publication Date
NZ504025A true NZ504025A (en) 2003-04-29

Family

ID=26663102

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504025A NZ504025A (en) 1997-10-14 1998-08-31 Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease

Country Status (9)

Country Link
EP (1) EP1023323A1 (en)
JP (1) JP2001519441A (en)
KR (1) KR20010031120A (en)
CN (1) CN1134452C (en)
AU (1) AU732079B2 (en)
CA (1) CA2306453A1 (en)
NZ (1) NZ504025A (en)
SE (1) SE9801148D0 (en)
WO (1) WO1999019354A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315529A1 (en) * 1997-12-12 1999-06-24 Merck & Co., Inc. Dna molecules encoding human nuclear receptor proteins, nnr7 and nnr7-1
US6911537B2 (en) * 1998-01-09 2005-06-28 The Salk Institute For Biological Studies Xenobiotic compound modulated expression systems and uses therefor
US6756491B2 (en) * 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
US6984773B1 (en) 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
AU2003200641B2 (en) * 1998-01-09 2008-04-03 The Salk Institute For Biological Studies Novel Steroid-activated Nuclear Receptors and Uses therefor
EP1066320A4 (en) * 1998-03-27 2005-03-16 Glaxo Group Ltd Orphan nuclear receptor
US7238491B1 (en) 1998-03-27 2007-07-03 Smithkline Beecham Corporation Pregnane X receptor method
FR2801311B1 (en) * 1999-11-22 2005-08-26 Centre Nat Rech Scient POLYPEPTIDES DERIVED FROM THE NUCLEAR RECEPTOR OF VITAMIN D, AND USES THEREOF IN PARTICULAR IN THE SCREENING OF ANALOGUES OF VITAMIN D
AU2006200258B2 (en) * 1999-12-09 2009-04-09 The Salk Institute For Biological Studies Novel steroid-activated nuclear receptors and uses therefor
US6514941B1 (en) 1999-12-10 2003-02-04 Campina Melkunie B.V. Method of preparing a casein hydrolysate enriched in anti-hypertensive peptides
US20040053866A1 (en) * 2002-08-21 2004-03-18 The Regents Of The University Of California Tumor suppressor genes and their uses
SE0400489D0 (en) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504438A (en) * 1988-03-30 1991-10-03 アーチ　デベロプメント　コーポレイション DNA-binding proteins including androgen receptors
DE69232537T2 (en) * 1991-09-17 2002-10-24 Salk Inst For Biolog Studies L RECEPTORS OF THE STEROID / THYROID SUPERFAMILY OF RECEPTORS
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
CA2210679A1 (en) * 1995-01-17 1996-07-25 The Salk Institute For Biological Studies Methods, polypeptides, nucleotide sequence of xor-6, a vitamin d-like receptor from xenopus
WO1996036230A1 (en) * 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulators for new members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
AU732079B2 (en) 2001-04-12
JP2001519441A (en) 2001-10-23
CA2306453A1 (en) 1999-04-22
KR20010031120A (en) 2001-04-16
SE9801148D0 (en) 1998-03-31
EP1023323A1 (en) 2000-08-02
CN1279689A (en) 2001-01-10
AU9013198A (en) 1999-05-03
CN1134452C (en) 2004-01-14
WO1999019354A1 (en) 1999-04-22
WO1999019354A9 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
Sorensen et al. Identification of the interleukin-3 receptor using an iodinatable, cleavable, photoreactive cross-linking agent.
Liu et al. Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA
DE69230888D1 (en) SOMATOSTATIN RECEPTORS
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
DE69839340D1 (en) Mutants of the VASCULAR, ENDOTHELCELL SPECIFIC GROWTH FACTOR C (VEGF-C) AND THEIR USES
Perrin et al. Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor
Hervé et al. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human α1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on α1-acid glycoprotein
Chen et al. The role of receptor dimerization domain residues in growth hormone signaling
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
DE69232537T2 (en) RECEPTORS OF THE STEROID / THYROID SUPERFAMILY OF RECEPTORS
DE69836956D1 (en) RECEPTOR 5 CONTAINING A DOMAIN RESPONSIBLE FOR CELL DEATH
NZ504025A (en) Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
DE69834027D1 (en) TUMOR NECROSIS FACTOR RECEPTOR 5
DK0559884T4 (en) Recombinant viral vectors for expression in muscle cells
BR9707379A (en) Isolated human antibody Isolated nucleic acid recombinant host cell expression vector process to synthesize a human antibody that binds to TNF Human alpha pharmaceutical composition process to inhibit human TNF activity and use of the antibody
WO2005058815A3 (en) Ip-10 antibodies and their uses
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
DE68928137T2 (en) DOPAMINE RECEPTORS AND GENES
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
DE69535641D1 (en) Morphogenic protein-specific cell surface receptors and their uses
WO1996015144A3 (en) Chromosome 21 gene marker, compositions and methods using same
Malany et al. Orientation of α-neurotoxin at the subunit interfaces of the nicotinic acetylcholine receptor
MXPA02008239A (en) Human schizophrenia gene.
WO1994028132A3 (en) Opioid receptors: compositions and methods
Williams et al. Rolloamides A and B, cytotoxic cyclic heptapeptides isolated from the Caribbean marine sponge Eurypon laughlini

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: BIOVITRUM AB, SE

Free format text: OLD OWNER(S): PHARMACIA AND UPJOHN AB

RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)